Oscient kept at market outperform by JMP

Oscient Pharmaceuticals Corp. was reiterated at market outperform by JMP Securities analyst Adam Cutler on news that Oscient acquired worldwide rights and assumed full control of Ramoplanin manufacturing, development and commercialization. Oscient needs cash, and Merrill believes a Ramoplanin licensing deal could bring in some cash and/or offset the costs of Ramoplanin development. Shares of the Waltham, Mass., pharmaceutical company were down 20 cents, or 8.89%, at $2.05 on volume of 800,946 shares versus the three-month running average of 557,619 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.